Department of Pediatrics, Icahn School of Medicine at Mount Sinai, Kravis Children's Hospital, New York, New York, USA.
Department of Psychology, Fordham University, Bronx, New York, USA.
Am J Transplant. 2021 Sep;21(9):3112-3122. doi: 10.1111/ajt.16567. Epub 2021 Apr 12.
Remote interventions are increasingly used in transplant medicine but have rarely been rigorously evaluated. We investigated a remote intervention targeting immunosuppressant management in pediatric lung transplant recipients. Patients were recruited from a larger multisite trial if they had a Medication Level Variability Index (MLVI) ≥2.0, indicating worrisome tacrolimus level fluctuation. The manualized intervention included three weekly phone calls and regular follow-up calls. A comparison group included patients who met enrollment criteria after the subprotocol ended. Outcomes were defined before the intent-to-treat analysis. Feasibility was defined as ≥50% of participants completing the weekly calls. MLVI was compared pre- and 180 days postenrollment and between intervention and comparison groups. Of 18 eligible patients, 15 enrolled. Seven additional patients served as the comparison. Seventy-five percent of participants completed ≥3 weekly calls; average time on protocol was 257.7 days. Average intervention group MLVI was significantly lower (indicating improved blood level stability) at 180 days postenrollment (2.9 ± 1.29) compared with pre-enrollment (4.6 ± 2.10), p = .02. At 180 days, MLVI decreased by 1.6 points in the intervention group but increased by 0.6 in the comparison group (p = .054). Participants successfully engaged in a long-term remote intervention, and their medication blood levels stabilized. NCT02266888.
远程干预在移植医学中越来越多地被使用,但很少被严格评估。我们研究了一种针对小儿肺移植受者免疫抑制剂管理的远程干预措施。如果患者的药物水平变异指数(MLVI)≥2.0,表明他的他克莫司水平波动令人担忧,则患者会从更大的多中心试验中被招募。该方案包括每周三次电话和定期随访电话。对照组患者则在该子方案结束后符合入组标准。在进行意向治疗分析之前,定义了结局。如果有≥50%的参与者完成了每周的电话随访,则认为该研究是可行的。在入组前和入组后 180 天比较 MLVI,并比较干预组和对照组。在 18 名合格患者中,有 15 名患者入组。另外有 7 名患者作为对照组。75%的参与者完成了≥3 次每周电话随访;平均协议时间为 257.7 天。与入组前相比,干预组患者入组后 180 天的 MLVI 显著降低(表明血液水平稳定性提高),为 2.9±1.29,p=0.02。在 180 天时,干预组的 MLVI 降低了 1.6 点,而对照组增加了 0.6 点(p=0.054)。参与者成功参与了一项长期的远程干预措施,他们的药物血液水平稳定下来。NCT02266888。